4 research outputs found
Acoustic Changes during Passage Reading in Speakers with Parkinson\u27s Disease
Purpose: The purpose of this study was to evaluate speech changes in Parkinson’s disease (PD) while reading a passage, using both local (i.e., segment level) and global (i.e., utterance level) acoustic measures.
Methods: 20 speakers participated in the study (10 PD, 10 neurologically healthy controls). The speakers were asked to read The Caterpillar passage in a conversational mode. A total of five acoustic measures were included (local: vowel duration, Euclidean distance between corner vowels and schwa; global: articulation rate, F0/intensity range). These acoustic measures were compared between two sentences located in the two positions within the paragraph, initial and final.
Results: The findings indicated (1) overall speech differences between the two groups such as increased vowel duration and reduced vowel contrast and (2) speech differences between the beginning and end of the passage such as increased articulation rate toward the end. In addition, the results revealed that unlike control speakers, speakers with PD did not show a greater F0 and intensity range in the end compared to the beginning of the passage, which points a limited capability of prosody modulations in PD and its apparent pattern toward the end of passage reading.
Discussion: Findings of this study support the notion that within- or across-task acoustic variation should be considered in speech sampling in clinical practice and research
FoxA2 Involvement in Suppression of Protein C, an Outcome Predictor in Experimental Sepsis
Low levels of protein C (PC) predict outcome as early as 10 h after insult in a rat polymicrobial sepsis model and were associated with suppression of PC mRNA, upstream transcription factor FoxA2, and cofactor hepatocyte nuclear factor 6 (HNF6). Small interfering RNA suppression of FoxA2 in isolated hepatocytes demonstrated regulation of both its cofactor HNF6 and PC. Our data suggest that reduced FoxA2 may be important in the suppression of PC and resulting poor outcome in sepsis
Recommended from our members
Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts
OBJECTIVE To assess the progression of type 1 diabetes using time to peak glucose or C-peptide during oral glucose tolerance tests (OGTTs) in autoantibody-positive relatives of people with type 1 diabetes. RESEARCH DESIGN AND METHODS We examined 2-h OGTTs of participants in the Diabetes Prevention Trial Type 1 (DPT-1) and TrialNet Pathway to Prevention (PTP) studies. We included 706 DPT-1 participants (mean ± SD age, 13.84 ± 9.53 years; BMI Z-score, 0.33 ± 1.07; 56.1% male) and 3,720 PTP participants (age, 16.01 ± 12.33 years; BMI Z-score, 0.66 ± 1.3; 49.7% male). Log-rank testing and Cox regression analyses with adjustments (age, sex, race, BMI Z-score, HOMA-insulin resistance, and peak glucose/C-peptide levels, respectively) were performed. RESULTS In each of DPT-1 and PTP, higher 5-year diabetes progression risk was seen in those with time to peak glucose >30 min and time to peak C-peptide >60 min (P < 0.001 for all groups), before and after adjustments. In models examining strength of association with diabetes development, associations were greater for time to peak C-peptide versus peak C-peptide value (DPT-1: χ2 = 25.76 vs. χ2 = 8.62; PTP: χ2 = 149.19 vs. χ2 = 79.98; all P < 0.001). Changes in the percentage of individuals with delayed glucose and/or C-peptide peaks were noted over time. CONCLUSIONS In two independent at-risk populations, we show that those with delayed OGTT peak times for glucose or C-peptide are at higher risk of diabetes development within 5 years, independent of peak levels. Moreover, time to peak C-peptide appears more predictive than the peak level, suggesting its potential use as a specific biomarker for diabetes progression